Navigation Links
Par Pharmaceutical Receives Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
Date:8/20/2013

WOODCLIFF LAKE, N.J., Aug. 20, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (sANDA) for bupropion hydrochloride (HCl) extended-release (ER) tablets USP (XL), 300 mg.  Bupropion HCl ER tablets USP (XL) is the generic version of WELLBUTRIN XL® and is indicated for the treatment of major depressive disorder (MDD).  Par's supply to the market of bupropion HCl ER tablets USP (XL), 150 mg and 300 mg, has been uninterrupted since originally approved in December 2006. 

In September 2012, FDA requested all generic drug companies marketing a version of bupropion HCl ER tablets, 300 mg, to conduct a fasting bioequivalence (BE) study comparing their bupropion HCl ER tablets, 300 mg, to GSK's WELLBUTRIN XL® (bupropion hydrochloride extended release) Tablets, 300 mg.  In December 2012, Par submitted a sANDA containing the requested study to FDA, which demonstrated in vivo bioequivalence of Par's bupropion HCl ER tablets USP (XL), 300 mg, to WELLBUTRIN XL® Tablets, 300 mg.  In April 2013, Par's sANDA was approved. 

Important Information About Bupropion HCl ER Tablets (XL) 
Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a seizure disorder, in patients treated with ZYBAN® (bupropion hydrochloride extended-release tablets (XL)); WELLBUTRIN® (bupropion hydrochloride tablets), the immediate-release formulation; WELLBUTRIN SR® (bupropion hydrochloride extended-release tablets (SR)), the sustained-release formulation; or any other medications that contain bupropion because the incidence of seizure is dose dependent, in patients with a current or prior diagnosis of bulimia or anorexia nervosa because of a higher incidence of seizures noted in patients treated for bulimia with the immediate-release formulation of bupropion, and in patients undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines). 

The concurrent administration of bupropion hydrochloride extended-release tablets (XL) and a monoamine oxidase (MAO) inhibitor is contraindicated.  At least 14 days should elapse between discontinuation of an MAO inhibitor and initiation of treatment with bupropion hydrochloride extended-release tablets (XL). 

Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients who have shown an allergic response to bupropion or the other ingredients that make up bupropion hydrochloride extended-release tablets (XL). 

A black box warning is associated with this product regarding Suicidality and Antidepressant Drugs.  Refer to full prescribing information for complete boxed warning. 

About Par Pharmaceutical Companies, Inc. 
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals.  For press release and other company information, visit www.parpharm.com


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals Provides Baby Quest Foundation Grant Recipients with Free Access to Fertility Medication
2. Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.
3. HedgePath Pharmaceuticals, Inc. Completes Reorganization Plan with Commonwealth Biotechnologies
4. National Pharmaceutical Council Studies New Formulary Decision-Making Tool
5. TetraLogic Pharmaceuticals Announces New Executives
6. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
7. Velocity Pharmaceutical Development and Remeditex Ventures Announce Collaboration Agreement and Initial Co-Investment
8. Pharmaceutical Companies Can Avoid Costly Launch Expenses by Leveraging and Pooling Sales and Promotional Resources
9. Cadence Pharmaceuticals Comments on USPTOs Non-Final, Initial Office Action on Reexamination of Patent
10. Japan Pharmaceutical Market Outlook
11. Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , January 23, 2017 Ahead of ... to see how they have fared at the close: Kite Pharma ... Inc. (NASDAQ: OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... Biotechnology shares were relative laggards on Friday, January 20 th , ... our complimentary research reports on these stocks now at: ...
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
(Date:1/23/2017)... Jan. 23, 2017 Just two weeks remain until legal experts ... gather in Central London to discuss the flow ... in the market, Parallel Trade 2017 . In the ... of attendees which is available to read in the event download ... Some of ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... 23, 2017 , ... The American Academy of Thermology ... development, healthcare training and clinical application of medical infrared imaging, has announced the ... Qualification Courses for Technicians, respectively. , For the first time the AAT is ...
(Date:1/23/2017)... Oregon (PRWEB) , ... January 23, 2017 , ... ... announced today it has earned organic certification under the USDA National Organic Program ... USDA Organic Certification process, we have established organic production and handling systems to ...
(Date:1/23/2017)... Georgia (PRWEB) , ... January 23, 2017 , ... ... in providing high-quality general gynecological care and gynecological services for women ... providing personalized care for a wide variety of reproductive services from routine health ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: an ... an early age. “Life Under Blankets” is the creation of published author, Kimberly Mitchell, ... Campus in Chicago. She went on to pursue a master’s degree in education in ...
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing ... big-name retail buyers at the January ECRM Trade Show in Hilton Head, SC. , ... safety standards in all of its creations to help create a more traditional and ...
Breaking Medicine News(10 mins):